Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

280
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
280
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

394
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
394
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

258
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
258
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

196
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
196
Cancer Survival Analysis01:21

Cancer Survival Analysis

448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Censoring Survival Data01:09

Censoring Survival Data

228
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
228

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Standardized mean differences in meta-analysis: A tutorial.

Cochrane evidence synthesis and methods·2025
Same author

Standardised mean difference.

BMJ evidence-based medicine·2025
Same author

Risk ratios, odds ratios and the risk difference.

BMJ evidence-based medicine·2024
Same author

Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane.

BMJ evidence-based medicine·2023
Same author

Advocating for evidence-informed decisions to make healthcare fit for each person.

BMJ evidence-based medicine·2022
Same author

Development of a checklist to detect errors in meta-analyses in systematic reviews of interventions: study protocol.

F1000Research·2021
Same journal

Correction to: "Should We Adopt the Case Report Format to Report Challenges in Complicated Evidence Synthesis? A Proposal and Illustration of a Case Report of a Complex Search Strategy for Humanitarian Interventions" and "A New Process Model of Study Identification Specific to the Identification of Randomised Studies for Systematic Reviews of Medical Interventions".

Cochrane evidence synthesis and methods·2026
Same journal

Reinterpreting I<sup>2</sup> Thresholds: Toward Context-Specific Heterogeneity Assessment in Evidence Synthesis.

Cochrane evidence synthesis and methods·2026
Same journal

Better Together: Tools to Aid Patient and Public Involvement in Evidence Synthesis and the Need for Consensus on Essential Reporting Items.

Cochrane evidence synthesis and methods·2026
Same journal

An Open-Source Systematic Reviews Integrated System (OSSYRIS) - Streamlining Processes and Standardising Data Structures.

Cochrane evidence synthesis and methods·2026
Same journal

RETRACTION: Human-in-the-Loop Artificial Intelligence System for Systematic Literature Review: Methods and Validations for the AutoLit Review Software.

Cochrane evidence synthesis and methods·2026
Same journal

Do We Need Systematic Reviews of Research Priority Setting? A Proposal for a New Concept on Conducting Systematic Reviews of Research Priority Setting Exercises.

Cochrane evidence synthesis and methods·2026
関連記事をすべて見る

関連する実験動画

Updated: Sep 9, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

タイム・トゥ・イベント・データを用いたメタ分析:チュートリアル

Ashma Krishan1, Kerry Dwan2

  • 1Centre for Biostatistics The University of Manchester, Manchester Academic Health Science Centre Manchester UK.

Cochrane evidence synthesis and methods
|August 28, 2025
PubMed
まとめ
この要約は機械生成です。

このチュートリアルでは,メタアナリシスの時事データに対する危険比について説明します. 実例とマイクロラーニングモジュールで解釈と計算方法を学びます.

さらに関連する動画

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

694
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K

関連する実験動画

Last Updated: Sep 9, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

694
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K

科学分野:

  • バイオ統計学
  • 臨床試験の方法論

背景:

  • 臨床試験では 発生までの時間が重要です
  • このようなデータのメタ分析には,特定の統計的アプローチが必要です.

研究 の 目的:

  • ハザード比の理解と利用に関するチュートリアルを提供すること.
  • メタアナリシスにタイム・トゥ・イベントのデータを含めることを実証する.

主な方法:

  • 危険性比の説明と解釈
  • イベントまでのデータに対するメタ分析の技術を実証する.
  • 実践のためのマイクロラーニングモジュールの提供

主要な成果:

  • ハザード比の概念を明確に説明する.
  • メタアナリシスを示した実例
  • ハザード比の計算のためのインタラクティブな練習の機会.

結論:

  • 研究者のための危険比率の理解を深める
  • タイム・トゥ・イベントの結果によるメタ分析を行う能力の向上
  • 臨床研究における生体統計学的方法に関する学習リソース